Inmedical Therapeutics Overview
- Year Founded
-
2020
- Status
-
Private
- Latest Deal Type
-
Early Stage VC
- Latest Deal Amount
-
$879K
- Investors
-
9
Inmedical Therapeutics General Information
Description
Developer of a gel-based device designed for healing of wounds. The company's device covers bedsores produced by resection to prevent complications such as the risk of delayed bleeding due to post-intervention perforation, enabling clients to help in active treatment and physiological healing of tissues while offering a mechanical-protective barrier that regenerates the colonic mucosa.
Contact Information
Website
www.inmedicaltherapeutics.comCorporate Office
- Calle Albert Einstein, 15
- Parque tecnológico de Álava
- 01510 Vitoria-Gasteiz
- Spain
Corporate Office
- Calle Albert Einstein, 15
- Parque tecnológico de Álava
- 01510 Vitoria-Gasteiz
- Spain
Inmedical Therapeutics Timeline
Inmedical Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC | 17-Jan-2024 | $879K | Completed | Clinical Trials - Phase 1 | ||
| 1. Accelerator/Incubator | 01-Sep-2023 | Completed | Startup |
Inmedical Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary |
Inmedical Therapeutics Patents
Inmedical Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024294287-A1 | Topical composition for the treatment of mucosal lesions with short gelling time | Pending | 20-Jul-2023 | ||
| EP-4746930-A1 | Topical composition for the treatment of mucosal lesions with short gelling time | Pending | 20-Jul-2023 | ||
| US-20260041705-A1 | Topical composition for the treatment of mucosal lesions with short gelling time | Pending | 20-Jul-2023 | ||
| US-20260294959-A1 | Topical composition for the treatment of mucosal lesions with short gelling time | Pending | 20-Jul-2023 | ||
| WO-2025017165-A1 | Topical composition for the treatment of mucosal lesions with short gelling time | Inactive | 20-Jul-2023 | A61L24/0015 |
Inmedical Therapeutics Investors (9)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Basque FCR | Corporation | Minority | ||
| Gestión de Capital Riesgo del País Vasco | Venture Capital | Minority | ||
| i+Med, S. Coop | Corporation | Minority | ||
| Jambo Healthcare | Venture Capital | Minority | ||
| Lizaluc | Venture Capital | Minority |
Inmedical Therapeutics FAQs
-
When was Inmedical Therapeutics founded?
Inmedical Therapeutics was founded in 2020.
-
Where is Inmedical Therapeutics headquartered?
Inmedical Therapeutics is headquartered in Vitoria-Gasteiz, Spain.
-
What industry is Inmedical Therapeutics in?
Inmedical Therapeutics’s primary industry is Therapeutic Devices.
-
Is Inmedical Therapeutics a private or public company?
Inmedical Therapeutics is a Private company.
-
What is the current valuation of Inmedical Therapeutics?
The current valuation of Inmedical Therapeutics is .
-
What is Inmedical Therapeutics’s current revenue?
The current revenue for Inmedical Therapeutics is .
-
How much funding has Inmedical Therapeutics raised over time?
Inmedical Therapeutics has raised $879K.
-
Who are Inmedical Therapeutics’s investors?
Basque FCR, Gestión de Capital Riesgo del País Vasco, i+Med, S. Coop, Jambo Healthcare, and Lizaluc are 5 of 9 investors who have invested in Inmedical Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process